Efficacy News and Research

RSS

Elan first quarter total revenue increases 17% to $288.4 million

Elan Corporation, plc, today reported its first quarter 2012 financial results.

26 Apr 2012

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

25 Apr 2012

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

25 Apr 2012

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Today Biogen Idec announced that detailed positive data from CONFIRM, the second Phase 3 clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS), will be presented in three platform presentations at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans.

25 Apr 2012

Study investigates how vitamin D affects skeleton when serum calcium levels are depleted

Vitamin D is renowned for its role in creating strong bones and is a key regulator of serum calcium levels. Calcium is primarily obtained through diet and absorbed through the intestine and into the blood stream. In addition to building bone, calcium is required for a variety of important physiological processes. Vitamin D, which is detected by receptors in bone and intestinal cells, regulates the level of calcium in the blood stream and determines how much should be stored in the skeleton.

24 Apr 2012

Nordion announces additional TheraSphere Phase III trial for HCC

Nordion Inc., a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced an additional randomized, multi-centre Phase III clinical trial for TheraSphere, Nordion's yttrium-90 (Y-90) glass microsphere treatment for liver cancer.

24 Apr 2012

Study shows how acupuncture therapy holds promise for skeletal muscle atrophy

A team of Japanese researchers will reveal study results Monday at the Experimental Biology 2012 meeting that show how acupuncture therapy mitigates skeletal muscle loss and holds promise for those seeking improved mobility through muscle rejuvenation.

24 Apr 2012

TGA approves Ikaria’s LUCASSIN to treat Hepatorenal Syndrome Type 1

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, announced today the approval of LUCASSIN (terlipressin) by the Therapeutic Goods Administration (TGA) of Australia.

24 Apr 2012

Beta cells from genetically modified pigs can effectively restore pancreas function

Transplantation of a whole pancreas or isolated insulin-producing beta cells are the only therapy to cure type 1 diabetes. However, the shortage of organ donors limits this approach to only few patients. LMU researchers have now shown that beta cells from genetically modified pigs can effectively restore pancreas function and can protect porcine beta cells from immune rejection in animal models.

23 Apr 2012

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis.

23 Apr 2012

ActiViews CT-Guide Needle Guidance System for liver interventions receives FDA 510(k) clearance

ActiViews, Inc, a company pioneering the development of simple, accurate, and cost-effective surgical navigation solutions, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its flagship product, CT-Guide Needle Guidance System, for liver interventions.

23 Apr 2012

FDA extends review period for linaclotide NDA to treat constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).

23 Apr 2012

Scripps Florida scientist to develop new tests for aging and stress-associated diseases

A scientist from the Florida campus of The Scripps Research Institute has been awarded just over $1 million from the National Institutes of Health to develop a range of new tests that could lead to new treatments for a number of stress-associated and degenerative disorders of advancing age.

21 Apr 2012

Sequana Medical's ALFApump System safe and effective in managing ascites

Sequana Medical announced that initial results from the PIONEER Clinical Study of its ALFApump System were presented today at the 47th annual European Association for Study of the Liver Meeting in Barcelona.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

Study shows efficacy of Infant Behavior, Cry and Sleep Clinic's model of integrated care

Having a new baby brings much joy to a new family. But for a family whose baby cries for hours on end, fusses through feedings, or has difficulty sleeping, the joy may be overshadowed by feelings of helplessness and frustration. The treatment of that infant - and that family - will impact the parent-child relationship for years to come.

20 Apr 2012

Patients with head and neck cancer can benefit from swallowing exercises

Mount Sinai School of Medicine researchers have found that targeted swallowing exercises can help alleviate swallowing dysfunction - a debilitating side effect in people undergoing chemoradiation therapy (CRT) for head and neck cancer.

20 Apr 2012

SK Biopharmaceuticals receives FDA Orphan Drug status for carisbamate

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that it was granted special status by the U.S. Food and Drug Administration (FDA) for carisbamate for the management of patients with infantile spasms (IS), a form of epilepsy associated with increased risk of death or mental retardation.

20 Apr 2012

Efficacy News and Research

Elan first quarter total revenue increases 17% to $288.4 million

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Study investigates how vitamin D affects skeleton when serum calcium levels are depleted

Nordion announces additional TheraSphere Phase III trial for HCC

Study shows how acupuncture therapy holds promise for skeletal muscle atrophy

TGA approves Ikaria’s LUCASSIN to treat Hepatorenal Syndrome Type 1

Beta cells from genetically modified pigs can effectively restore pancreas function

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

ActiViews CT-Guide Needle Guidance System for liver interventions receives FDA 510(k) clearance

FDA extends review period for linaclotide NDA to treat constipation

Scripps Florida scientist to develop new tests for aging and stress-associated diseases

Sequana Medical's ALFApump System safe and effective in managing ascites

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

New data provides hope for HCV non-responders

New data shows consolidation of interferon-free revolution in HCV treatment

Study shows efficacy of Infant Behavior, Cry and Sleep Clinic's model of integrated care

Patients with head and neck cancer can benefit from swallowing exercises

SK Biopharmaceuticals receives FDA Orphan Drug status for carisbamate

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News